Cytopia zeroes in on brain
Monday, 17 November, 2008
Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.
The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.
CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.
The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
